- Raised $1M funding round, Dec 2019
- Raised $4M funding round, Jul 2018
- Raised funding round, Sep 2021
About
NewStem has developed a novel technology for predicting resistance to anticancer treatments. The company is creating a diagnostic tool based on pioneering research in the field of human haploid pluripotent stem cells (HHPSCs), which are used for a variety of applications, ranging from basic research to therapeutics. Anticancer treatment often results in tumor resistance to the drugs used. Due to the differentiation capacity of pluripotent stem cells, one potential use is to assess the influence of mutated genes on a variety of cells, physiological processes, and drug responses. Human cells contain two copies of each gene (diploid cells), making it difficult to generate cells in which both copies of the relevant genes are mutated. NewStems findings enable the generation of fully functional stem cells containing only one copy of each gene (haploid cells). A unique and broad library of HHPSCs with different mutations and genetic makeups is enabling NewStem to develop diagnostic tools for personalized medicine. NewStem is a spin-off of Yissum Research Development Company of the Hebrew University of Jerusalem.
Funding history · 3 rounds · $5.0M total
Q&A
- What is NewStem's primary focus?
- NewStem is focused on precision medicine therapeutics, specifically developing a novel technology for predicting resistance to anticancer treatments using human haploid pluripotent stem cells (HHPSCs).
- What is the current status of NewStem?
- NewStem is currently inactive and ceased to operate in October 2024.
- When was NewStem founded?
- NewStem was founded in September 2016.
- Who is the CEO of NewStem?
- Ayelet Dilion-Mashiah is the CEO of NewStem.
- What was NewStem's last known funding round?
- NewStem's last known funding round occurred in September 2021, with Illumina Accelerator Cambridge participating.
- What is NewStem's total funding raised to date?
- NewStem has raised a total of $5,000,000 USD across its funding rounds.
- Which investor participated in NewStem's July 2018 funding round?
- NovelStem International Corp participated in NewStem's funding round in July 2018.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/11802392 | |
| YouTube | youtube.com/channel/UCoeRaNC-_V7xIZM9An8Qzlw |
Identifiers & details
| Founded | 2016-9 |
|---|---|
| Employees (exact) | 3 |
| Status reason | Non Active, Oct 2024 ceased to operate |